667 lp - see footnote investment history in Incyte corp

Filed on 2013-06-13 by 667, L.P. SEC CIK 1551139 Form 3

Accession 0001144204-13-034804.txt Sec File: edgar/data/1551139/0001144204-13-034804-index.htm

2013-06-11 667 Lp (CIK 1551139) through See Footnote

Invested in Incyte Corp remaining shares owned 15000

Common Stock Incyte Corp Incy

f2 these shares of common stock were received upon exercise of stock options that were issued to julian c. baker in his capacity as director of the issuer. julian c. baker serves on the issuer's board of directors (the "board") as a representative of 667. julian c. baker, pursuant to the policies of the adviser, did not have any right to the pecuniary interest in the stock options issued for his service on the board or the shares of common stock received upon exercise of such stock options. 14159, l.p. ("14159") with 667, l.p. and baker brothers life sciences, l.p. (collectively, the "funds") owns an indirect proportionate pecuniary interest in the shares of common stock received upon exercise of the stock options issued in connection with julian c. baker's service on the board less the cost to julian c. baker of exercising those options. solely as a result of their ownership interest in the general partners of the general partners of the funds, felix j. baker and julian c. baker may be deemed to have an indirect pecuniary interest in the shares issued upon exercise of the stock options (i.e. no direct pecuniary interest). the shares of common stock issued upon exercise of the stock options reported herein have been previously reported by julian c. baker.


Filed on 2013-06-13 by 667, L.P. SEC CIK 1551139 Form 3

Accession 0001144204-13-034804.txt Sec File: edgar/data/1551139/0001144204-13-034804-index.htm

2013-06-11 667 Lp (CIK 1551139) through See Footnote

Invested in Incyte Corp remaining shares owned 2023937

Common Stock Incyte Corp Incy

f1 the shares of common stock of incyte corporation (the "issuer") reported herein are held directly by 667, l.p. ("667"), a limited partnership the sole general partner of which is baker biotech capital, l.p., a limited partnership the sole general partner of which is baker biotech capital (gp), llc. julian c. baker and felix j. baker are the controlling members of baker biotech capital (gp), llc. baker bros. advisors, llc (the "adviser") serves as the investment adviser to 667. in connection with the services provided by the adviser, the adviser receives an asset-based management fee that does not confer any pecuniary interest. on april 12, 2012, the adviser, 667 and the general partner of 667 entered into an amended and restated management agreement which gave the adviser complete and unlimited discretion and authority with respect to 667's investments and voting power over investments. the general partner of 667 relinquished all discretion and authority with respect to 667's investments and voting power over investments. julian c. baker and felix j. baker each may be deemed to control the adviser and to indirectly beneficially own the shares beneficially owned by it. julian c. baker and felix j. baker disclaim beneficial ownership of these securities, except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that felix j. baker or julian c. baker is the beneficial owner of the above referenced securities for purposes of section 16 or for any other purpose. the shares reported herein have been previously reported by felix j. baker, julian c. baker and the adviser in their own section 16 reports. in the future, 667 may jointly file section 16 reports with julian c. baker, felix j. baker and the adviser.